The underestimated risk of additional ipsilateral BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients.

Authors

Yue Hu, Hongli Wang, Mengzi Wu, Wei Zheng, Jingsi Mei, Xiaofang Jiang, Queran Lin, Ran Gu, Fengtao Liu, Jinna Lin, Chang Gong, Jun Shen, Qiang Liu

Published in

Insights into imaging. Volume 17. Issue 1. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

To determine the prevalence of malignancy of additional ultrasound BI-RADS category 3 lesions in women with newly diagnosed breast cancer.
Between July 2014 and June 2022, women with newly diagnosed breast cancer and additional ultrasound BI-RADS 3 lesions were retrospectively included. Malignancy was confirmed by pathology, and malignancy rates were assessed at both the patient and lesion levels. Independent risk factors for malignant BI-RADS 3 lesions were identified using multivariable logistic regression.
A total of 1458 women (median age, 45 years; IQR: 40-51) with 1995 ultrasound BI-RADS 3 lesions were included. At the patient level, malignancy was identified in 3.5% of patients (51/1458), with higher rates for ipsilateral than contralateral BI-RADS 3 lesions (9.8% [39/397] vs 1.1% [12/1061]; p < 0.001). At the lesion level, the overall malignancy rate was 2.7% (54/1995), similarly elevated for ipsilateral compared with contralateral lesions (7.5% [41/544] vs 0.9% [13/1451]; p < 0.001). Independent predictors for malignancy of ipsilateral BI-RADS 3 lesions included same-quadrant location as the primary lesion (OR, 4.3; 95% CI: 1.9, 9.7; p < 0.001), ultrasonographic architectural distortion of the primary lesion (OR, 8.5; 95% CI: 1.6, 46.1; p = 0.01), and mammographic suspicious calcification of the primary lesion (OR, 2.9; 95% CI: 1.4, 6.0; p = 0.004).
Additional ipsilateral ultrasound BI-RADS 3 lesions in women with newly diagnosed breast cancer demonstrated malignancy rates exceeding the 2% BI-RADS threshold, particularly when located in the same quadrant as the primary cancer.
Question The malignancy risk of additional BI-RADS 3 lesions identified by preoperative ultrasound in breast cancer patients remains unclear. Findings Ipsilateral lesions, especially in the same quadrant, show malignancy rates exceeding 2%, while malignancy risk remains low for contralateral BI-RADS 3 lesions. Critical relevance statement Ipsilateral BI-RADS 3 lesions in the same quadrant as the primary cancer, or those with primary tumor architectural distortion or suspicious calcifications, warrant biopsy. This ensures precise surgical planning and avoids missing additional malignancy.

PMID:
42886330
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.